Polynovo Ltd
Company Profile
Business description
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
8
Polynovo Ltd News & Analysis
stocks
ASX healthcare stocks shrug off new tariff threat
stocks
The ASX’s most shorted stocks
stocks
Will CEO departure upend ASX healthcare leader?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,063.40 | 33.90 | 0.38% |
CAC 40 | 7,795.42 | 32.03 | -0.41% |
DAX 40 | 23,534.83 | 131.98 | -0.56% |
Dow JONES (US) | 46,053.51 | 67.77 | -0.15% |
FTSE 100 | 9,213.98 | 36.45 | -0.39% |
HKSE | 26,484.68 | 33.97 | -0.13% |
NASDAQ | 22,425.38 | 72.47 | -0.32% |
Nikkei 225 | 45,754.93 | 124.62 | 0.27% |
NZX 50 Index | 13,153.79 | 27.52 | -0.21% |
S&P 500 | 6,613.86 | 24.11 | -0.36% |
S&P/ASX 200 | 8,773.00 | 35.10 | 0.40% |
SSE Composite Index | 3,853.30 | 0.34 | -0.01% |